Sanofi (NYSE:SNY) said at the start of April that it promoted Bill Sibold to exec VP of Sanofi Genzyme, effective July 1, 2017. Sibold succeeds Dr. David Meeker, who is slated to leave the company at the end of June.
Sibold is the head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization. He led the company in preparation for the global launches of Dupilumab and Sarilumab. He joined Sanofi in 2011 as head of the MS business.
“With a strong commitment to serving patients, Sanofi Genzyme has evolved from a rare disease company into a preeminent specialty care business, deeply rooted in science. I am confident in Bill Sibold’s experience and leadership to build on this strong foundation as we chart the next chapter for Sanofi Genzyme, which has become a real growth driver for Sanofi” CEO Olivier Brandicourt said in prepared remarks. “I would also like to thank David Meeker for his tireless dedication to our shared vision for Sanofi Genzyme and his personal passion for the patients we serve, both of which helped make our company the success it is today.”
Sibold has worked at Eli Lilly and also held leadership positions at Biogen, where he guided their U.S. commercial operations in neurology, oncology and rheumatology. He also served as the chief commercial officer of Avanir Pharmaceuticals.
Earlier this month, Sanofi touted real-world clinical data for its Toujeo insulin glargine injection from a new observational study. The data from Deliver 2 showed that patients with Type II diabetes who switched to Toujeo from other basal insulins had significantly lower risk of hypoglycemia without compromising blood sugar control.
“George is a highly regarded financial professional, offering extensive expertise at high-growth private and public life sciences and technology,” president & CEO Amar Sawhney said. “We believe his insights will be invaluable as we continue to undertake pre-commercialization activities for Dextenza in advance of the July 19th PDUFA date and as we make further substantial progress across our additional drug product development programs.”
GlucoMe named John Erickson as exec VP and general manager of the company’s North American business. He previously served as divisional VP at Abbott, where he was responsible for diabetes products and strategy.
“I am very excited to join GlucoMe, and look forward to helping doctors and patients across the United States better treat diabetes,” Erickson said. “Diabetes management and care are major concerns for tens of millions of American patients, as well as healthcare payers and professionals. GlucoMe’s digital technology and strategic roadmap are opening up an exciting avenue to enable simpler and more effective diabetes care resulting in better outcomes. I look forward to working closely with the entire team as GlucoMe takes its next steps forward.”
He joins Mylan from consulting firm Patomak Global Partners.
Bausch & Lomb said that in an effort to restructure its U.S. management team, it has appointed 4 of its employees to new positions.
Senior VP & GM of U.S. consumer healthcare, Joseph Gordon, and senior VP & GM of U.S. pharmaceuticals, Travy Valorie, will have expanded roles to include the U.S. vision care biz and the U.S. surgical biz, respectively.
The company also said that it tapped John Ferris to be VP & GM for U.S. vision care and Chuck Hess will assume the role VP & GM for U.S. surgical.
“These management changes exemplify how we’re continuing to align our resources to be more responsive to the needs of the marketplace by increasing our efficiencies and creating opportunities for potential synergies that will ultimately help drive the company’s overall growth,” Valeant chairman & CEO Joseph Papa said.
- Pulmatrix brings on 2 fungal infection experts
- Alexion names CEO
- Sherman joins Silicon Therapeutics as CSO
- Gregory named to Iconic Therapeutics’ board of directors